Skip to main content

Table 1 Clinical and demographic data of ankylosing spondylitis patients at baseline

From: IL-23/Th17 axis is not influenced by TNF-blocking agents in ankylosing spondylitis patients

 

Ankylosing spondylitis (n = 86)

 

Variable

Active-AS

Control-AS

p value

 

(BASDAI ≥4; n = 47)

(BASDAI <4; n = 39)

 

Gender, male (%)

35 (74 %)

29 (74 %)

1.00

Age (years)

38.0 ± 11.1

49.5 ± 10.5

<0.001

Caucasian (%)

42 (89 %)

29 (74 %)

0.09

Peripheral involvement (%)

31 (66 %)

23 (59 %)

0.65

HLA-B27 positive (%)

82 %

90 %

0.36

Disease duration (years)

10.8 ± 4.5

17.6 ± 8.9

0.007

ASDAS-CRP

3.9 ± 1.0

2.0 ± 0.8

<0.001

BASFI

5.8 ± 2.3

3.8 ± 2.1

<0.001

BASMI

4.5 ± 2.7

5.8 ± 2.7

0.03

ASQoL

12.6 ± 4.8

5.3 ± 4.1

<0.001

CRP (mg/l)

29.7 ± 39.6

4.6 ± 3.5

<0.001

ESR (mm/hour)

29.7 ± 23.3

6.9 ± 6.6

<0.001

mSASSS

15.8 ± 18.9

37.9 ± 25.5

<0.001

NSAID intake score (0–100)

70.3 ± 44.8

68.3 ± 41.4

0.77

Methotrexate (%)

23 (48 %)

2 (0.5 %)

<0.001

Sulphasalazine (%)

27 (57 %)

21 (53 %)

0.83

Leflunomide (%)

2 (4.2 %)

1 (0.02 %)

1.00

  1. All values are expressed as the mean ± standard deviation, except proportions (%)
  2. Nonparametric tests were performed for data that failed the normal distribution
  3. AS ankylosing spondylitis, ASDAS-CRP Ankylosing Spondylitis Disease Activity Score-C-reactive protein, ASQoL Ankylosing Spondylitis Quality of Life, BASDAI Bath Ankylosing Spondylitis Disease Activity Index, BASFI Bath AS Functional Index, BASMI Bath Ankylosing Spondylitis Metrology Index, CRP C-reactive protein, ESR erythrocyte sedimentation rate, mSASSS modified Stoke Ankylosing Spondylitis Spine Score, NSAID nonsteroidal anti-inflammatory drug
Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us